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A B S T R A C T
Our objective was to determine whether consumption of a single meal has the potential to alter brain oxylipin
content. We examined the cerebrum of mice fed a single high-fat/high-sucrose Western meal or a low-fat/low-
sucrose control meal, as well as fasted mice. We found no changes in fatty acid composition of cerebrum across
the groups. The cerebral oxylipin proﬁle of mice fed a Western meal is distinct from the proﬁle of mice fed a low-
fat/low-sucrose meal. Cerebral gene expression of cyclooxygenase 1, cyclooxygenase 2, and epoxide hydrolase 1
were elevated in Western meal-fed mice compared to low-fat/low-sucrose meal-fed mice. Mice that consumed
either meal had lower gene expression of cytochrome P450, family 2, subfamily j, polypeptide 12 than fasted
mice. Our data in this hypothesis-generating study indicates that the composition of a single meal has the
potential to alter brain oxylipins and the gene expression of the enzymes responsible for their production.
1. Introduction
Aging is associated with cognitive decline and the development of
dementia, the prevalence of which has been increasing as the popula-
tion ages [1]. Further, neuroinﬂammation and oxidative stress are as-
sociated with aging and neurodegeneration [2]. Oxylipins are bioactive
products of polyunsaturated fatty acid oxidation, which have been
shown to be involved in regulating inﬂammation, oxidative stress, and
resolution pathways in brain [3]. Less is known about the role of oxy-
lipins in neurodegenerative diseases, however a few studies have in-
dicated a role of oxylipins in the modulation of Alzheimer's disease
progression and traumatic brain injury [4–9].
Certain dietary patterns are believed to modify the risk for devel-
oping cognitive decline [1]. Chronic consumption of a Western diet,
characterized as being high in fats and sugars, has been linked to an
increased risk of cognitive decline [10,11]. The Western diet has been
shown to impact many aspects of brain health including oxidative stress
and neuroinﬂammation [11]. In previous work conducted in our la-
boratory, we found that the consumption of a Western diet over the
period of three months increased arachidonic acid derived oxylipins
and altered the fatty acid proﬁles of the brains of mice [12]. Further,
others have shown that various modiﬁcations of a chronically con-
sumed diet have the potential to modify brain oxylipin levels [13–17].
To our knowledge, no studies have examined whether the con-
sumption of a single meal can alter brain fatty acid or oxylipin levels.
This may have implications for acutely modifying brain signaling and
inﬂammatory pathways in a manner that can potentially reduce the
brain's resilience to external insults. For instance, frequent but acute
reductions in protective anti-inﬂammatory oxylipins or increases in
pro-inﬂammatory oxylipins following a Western diet could potentially
accelerate age associated loss of function leading to dementia. The
objective of this study was to determine whether the consumption of a
single “Western diet” meal could impact brain fatty acid or oxylipin
composition. We asked two basic questions: 1) does the consumption of
a meal alter brain fatty acid and oxylipin levels when compared to the
fasted state? and 2) does the consumption of a “Western” meal alter the
fatty acid and oxylipin levels when compared to a low-fat/low-sucrose
meal? We meal-trained mice for eight days, then fed one group of mice
a “Western” meal, another an ingredient-matched low-fat/low-sucrose
meal, and a third group was analyzed while fasting. We examined
cerebrum fatty acid composition and oxylipin content. We then used
the results of these analyses to identify oxylipin-generating enzymes of
interest, for which we measured gene expression.
2. Materials and methods
2.1. Animals
C57Bl/6 J male mice were obtained from Jackson Laboratories at 17
weeks of age. All procedures were approved by the University of
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California, Davis Institutional Animal Care and Use Committee (pro-
tocol number 20068). These procedures were carried out in accordance
with the National Institutes of Health guide for the use and care of
laboratory animals.
2.2. Diets
The diets used in this study were an ingredient matched low-fat/
low-sucrose control diet (LFLSD, Envigo TD.08485) and a high-fat/
high-sucrose Western diet (WD, Envigo TD.88137). The LFLSD contains
3.6 kcal/g with 19.1% kcal from protein, 67.9% kcal from carbohy-
drate, and 13.0% kcal from fat, with 120 g/kg sucrose content. The fat
source for the LFLSD is 37.2 g/kg anhydrous milkfat and 12.8 g/kg
soybean oil. The calculated fatty acid content of the LFLSD provided by
the manufacturer can be found in Supplemental Table 1. The WD
contains 4.5 kcal/g with 15.2% kcal from protein, 42.7% kcal from
carbohydrate, and 42.0% kcal from fat, with 341.46 g/kg sucrose
content and 1.5 g/kg added cholesterol. The fat source for the WD is
210 g/kg anhydrous milkfat. The measured percent fatty acid compo-
sition of the WD provided by the manufacturer can be found in
Supplemental Table 2.
2.3. Meal training
Upon receipt at 17 weeks of age (n = 15), mice were given the
LFLSD ad libitum for 12–14 days. Following this adjustment period,
mice were trained to consume the food in a meal format for eight days.
The night before the initiation of the meal training procedure, all food
was removed from the cage. Each day of meal training the mice were
given a meal twice daily with at least 8 h between LFLSD meals. Each
meal consisted of access to an amount of food more than suﬃcient for
their daily intake requirements (at least 5 g per mouse) for 90 min. At
the end of the 90-minute period, any remaining food was removed from
the cage. Water access was never restricted during this process.
2.4. Test meal and tissue collection
The day of tissue collection immediately followed the eight days of
meal training. Mice were allocated to one of three groups: fasting
(n = 5), low-fat/low-sucrose meal (LFLSM, n = 5), or Western meal
(WM, n= 5). Mice in the LFLSM and WM groups were given access to a
weighed amount of LFLSD or WD, respectively, for a meal period lasting
90–120 min. Any remaining food was removed, weighed, and recorded
to determine the amount of food consumed. Four hours after the in-
itiation of the meal, tissues were collected. We chose the 4 h timepoint
based on previous ﬁndings that postprandial triglycerides peak at 3.5 h
after consumption of a meal [18]. Due to the long meal time in our
study (to ensure the mice ate a suﬃcient quantity), we measured the
time from meal initiation we added half an hour to approximate this
peak in triglycerides as best we could. For mice in the fasting group,
tissue was collected at the time of meal initiation for the other groups.
Prior to tissue collection, mice were given 1–5% isoﬂurane until
unresponsive to toe pinch. The chest cavity was then opened and the
mouse was exsanguinated and the heart removed to ensure euthanasia,
prior to tissue collection. The brain was collected and snap frozen in
liquid nitrogen within 5 min of death.
2.5. Free oxylipin extraction from brain
Most oxylipin and surrogate standards were obtained from Cayman
Chemicals (Ann Arbor, MI, USA). 9,12,13- trihydroxyoctadecenoic
(TriHOME) and 9,10,13-TriHOME were purchased from Loradan
(Solna, Sweden). Solvents were obtained from Fisher Scientiﬁc and
were all UPLC-MS grade.
The right hemisphere of cerebrum from each mouse
(112.7–247.7 mg) was homogenized in 200 μL of methanol containing
0.1% butylated hydroxytoluene (BHT). The samples were spiked with
10 µL of deuterated surrogate standard solution containing 2 μM of d11-
11(12)-EpETrE, d11-14,15-DiHETrE, d4-6-keto-PGF1α, d4-9-HODE,
d4-LTB4, d4-PGE2, d4-TXB2, d6-20-HETE and d8-5-HETE in methanol.
The samples were then precooled in −80 °C for 30 min and homo-
genized with a bead homogenizer (Nextadvance air cooling bullet
blender, Troy, NY, USA) using zirconia beads. The homogenized sam-
ples were centrifuged at 4 °C at a speed of 15,871 g for 10 min. The
supernatant was loaded onto 60 mg Waters Oasis HLB 3cc solid phase
extraction (SPE) columns (Waters, Milford, MA, USA), pre-rinsed with
one volume of ethyl acetate and two volumes of methanol, and pre-
conditioned with two volumes of SPE buﬀer containing 5% methanol
and 0.1% acetic acid in ultrapure Millipore water. The columns were
rinsed twice with SPE buﬀer and subjected to 20 min of vacuum
(≈20 psi). Oxylipins were eluted with 0.5 mL methanol and 1.5 mL
ethyl acetate into 2 mL centrifuge tubes, dried under nitrogen and re-
constituted in 100 µL methanol. Ten µL was analyzed by UPLC-MS/MS.
The remaining brain pellets were store at−80 °C for fatty acid analysis.
2.6. UHPLC-MS/MS analysis
All measured oxylipins are listed and abbreviated in Supplemental
Table 3. Oxylipins were analyzed by ultra-high-pressure liquid chro-
matography tandem mass spectrometry (UHPLC-MS/MS) using Agilent
LC system 1290 (Agilent Corporation, Santa Clara, CA, USA), coupled to
an Agilent 6460 Triple Quadrupole MS system (Agilent Corporation).
Oxylipin species were separated on an Agilent Eclipse Plus C18 column
(2.1 × 150 mm, 1.8 μm, Agilent Corporation) with a binary gradient
consisting of solvent A (water containing 0.1% acetic acid) and solvent
B (Acetonitrile: methanol 80:15 containing 0.1% acetic acid). The
column temperature was maintained at 45 °C. The gradient proﬁle is
shown in Supplemental Table 4. Electrospray ionization (negative
mode) was used as the ion source with the experimental parameters, as
follows: Gas temperature, 250 °C, Gas ﬂow, 10 L/min; Sheath gas
temperature, 300 °C; Sheath gas ﬂow, 11 mL/min; Nebulizers 35 psi;
Capillary gas, 3500 V/−3500 V. Optimization parameters and parent
and product ion monitoring pairs are described Supplemental Table 5.
Surrogate recovery data can be found in Supplemental Table 6, there
were no diﬀerences in surrogate percent recovery between groups.
Abbreviations
LFLSD low-fat/low-sucrose diet
LFLSM low-fat/low-sucrose meal
WD Western diet
WM Western meal
PGD1 prostaglandin D1
DiHETrE hydroxyeicosatrienoic acid
EpETrE epoxyeicosatrienoic acid
EpDPE epoxydocosapentaenoic acid
CYP2J12 cytochrome P450, family 2, subfamily j, polypeptide 12
COX cyclooxygenase
EPHX epoxide hydrolase
sEH soluble epoxide hydrolase
mEH microsomal epoxide hydrolase
DGLA dihomo-γ-linolenic acid
AA arachidonic acid
DHA docosahexaenoic acid
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2.7. Fatty acid derivatization
The remaining brain pellet from the oxylipin extraction (above) was
reconstituted in 1 mL methanol. Samples were vortexed and homo-
genized for 1 min in the bead homogenizer. Samples were transferred to
new glass tubes containing 400 μL toluene. Two mL methanol was
added to the old tubes, vortexed and the solution was transferred to
new glass tubes, 600 μL of 8% HCl (37% concentrated) in methanol
solution was added. The HCl used was 37% ACS reagent (Sigma
Aldrich, St. Louis, MO, USA). The samples were heated at 90 °C for
60 min on a heating block and were cooled down for 4 to 5 min
thereafter at room temperature. 1 mL of water and 1 mL of hexane were
then added to each sample. The samples were vortexed and centrifuged
on a Beckman Coulter Allegra 6 centrifuge (Beckman Coulter, Palo Alto,
CA, U.S.A.) using a GH3.8A rotor at 646 × g for 10 min. Then 900 μL of
the hexane layer was transferred to a micro-centrifuge tube (USA
Scientiﬁc, Orlando, FL, USA) containing 450 μL of distilled water,
vortexed and centrifuged for 2 min at 15,871 × g on a 5430r Eppendorf
micro‐centrifuge containing a FA‐45‐24‐11 rotor (Fisher Scientiﬁc,
Pittsburgh, PA, USA). The hexane upper layer was then transferred to a
new micro‐centrifuge tube, dried under nitrogen and reconstituted in
100 μL hexane. Samples were stored at −80 °C until analysis.
2.8. GC analysis
All samples were analyzed on a Perkin Elmer Clarus 500 GC system
with a ﬂame ionization detector (FID) (Perkin Elmer, Shelton, CT,
U.S.A.) equipped with a FFAP capillary column (30 m× 0.25 mm inner
diameter, 0.25 μm ﬁlm thickness; Agilent Technologies, Santa Clara,
Calif., U.S.A.). The injector and detector temperature were set at 240 °C
and 300 °C, respectively. The split ratio was 10:1 and the injection
volume was 1 μL. The initial oven temperature was 80 °C. It was held at
80 °C for 2 min, increased by 10 °C/min to 185 °C upon injection, then
to 240 °C at 5 °C/min and held at 240 °C for 13 min. The total run time
was 36.5 min. Helium was the carrier gas and was maintained at a ﬂow
rate of 1.3 mL/min. A custom mix of 29 fatty acid methyl ester stan-
dards was used to identify individual fatty acids based on retention
time. Data were expressed as percent of total identiﬁed fatty acid peaks.
2.9. Gene expression
The left hemisphere of cerebrum was powdered and used for ana-
lysis of gene expression. RNA was isolated from approximately 50 mg of
powdered tissue using Trizol and RNeasy mini kit according to the
manufacturer's instructions. RNA from each sample was quantiﬁed
using a Nanodrop ND-1000 Spectrophotometer, reverse transcribed
using Superscript III First Strand Synthesis Kit (Life Technologies) ac-
cording to manufacturer's instructions. qRT-PCR was performed with
SYBR Green PCR Mastermix (Applied Biosystems) to quantify the gene
expression. Reactions were carried out in 384-well optical plates con-
taining approximately 25 ng RNA in each well. The quantity of applied
RNA was normalized by simultaneously amplifying cDNA samples with
gene of interest speciﬁc primers and 18 s speciﬁc primers. The primer
sequences used can be found in Supplemental Table 7. Primer se-
quences were obtained from the Primer Bank at: https://pga.mgh.
harvard.edu/primerbank/ [19], with the exception of the primers for
CYP2J12 which was obtained from the publication by Graves and col-
leagues [20]. Transcript levels were measured by qRT-PCR using the
ABI Vii7 Sequence detection system (PE Applied Biosystems). The PCR
ampliﬁcation parameters were: initial denaturation step at 95 °C for
10 min followed by 40 cycles, each at 95 °C for 15 s (melting) and 60 °C
for 1 min (annealing and extension). A comparative threshold cycle (Ct)
method was used to calculate relative changes in gene expression de-
termined from qRT-PCR experiments [21]. The Ct, which correlates
inversely with the target mRNA levels, was measured as the cycle
number at which the SYBR Green emission increases above a preset
threshold level. Fold change determinations were made using the
LFLSM group as a reference.
2.10. Statistical analysis
Analysis of the oxylipin and fatty acid data as well as generation of
the sPLSDA plots was done using the publicly available software
Metaboanalyst 4.0 [22,23]. Oxylipins for which there were less than 3
samples per group with detectable amounts were excluded from these
analyses. For all other analyses, when comparing the two meal groups,
data was analyzed by t-test or Mann-Whitney Rank Sum Test (for data
that was not normally distributed). When comparing all three groups
ANOVA or ANOVA on Ranks (for data that was not normally dis-
tributed). For ANOVA analyses with a signiﬁcant result, a Holm-Sidak
post hoc (versus Fasting group mice) test was run to determine if one or
more of the meal consuming groups diﬀered from the fasting group.
Unless otherwise indicated data shown is mean ± standard deviation.
3. Results
3.1. Food consumption during meal period
There was no diﬀerence in the body weights of the animals allocated
to the fasting, low-fat/low-sucrose meal (LFLSM), and Western meal
(WM) groups as determined by one-way ANOVA (Fasting
27.9 ± 1.20 g; LFLSM 27.96 ± 1.17 g; WM 28.42 ± 1.20 g). Food
consumption during the test meal period, determined by the diﬀerence
in the weight of the food before the meal period and any remaining
food at the end of the meal period, was not signiﬁcantly diﬀerent be-
tween the two meal consuming groups. This also holds true when the
amount of food was normalized to bodyweight for each mouse.
However, due to the diﬀerence in the caloric density of the two diets,
the WM group did consume signiﬁcantly more kilocalories during the
meal period than the LFLSM group, regardless of if the caloric intake
was normalized to bodyweight (Table 1).
3.2. Cerebral oxylipin content
Brain free oxylipin content of the right hemisphere of cerebrum was
determined by UHPLC-MS/MS. The results of the analysis can be seen
in Table 2. When addressing the question of whether consuming a meal
alters brain oxylipin concentrations compared to the fasted state,
prostaglandin D1 (PGD1), and 14,15-dihydroxyeicosatrienoic acid
(DiHETrE) content were found to be signiﬁcantly higher in the WM
group compared to the fasted group, while the LFLSM group did not
diﬀer from the fasted group for any of the measured oxylipins. When
comparing the two meal consuming groups, four of the measured
oxylipins were signiﬁcantly diﬀerent between the LFLSM and WM
groups. PGD1, 14,15 DiHETrE, and 8,9-Epoxyeicosatrienoic acid
(EpETrE) were signiﬁcantly higher in the WM group when compared to
the LFLSM group. 16(17)-epoxydocosapentaenoic acid (EpDPE) was
Table 1
Bodyweight and food consumption during meal period.
Low-fat/low-sucrose
meal (LFLSM)
Western meal (WM) p value
Mean Standard
Deviation
Mean Standard
Deviation
t-test
Bodyweight (g) 27.96 1.17 28.42 1.20 0.558
Food consumed (g) 1.78 0.62 2.6 0.62 0.071
kcal consumed 6.408 2.24 11.7 2.81 0.011
g food consumed / g
bodyweight
0.064 0.024 0.092 0.022 0.095
kcal consumed / g
bodyweight
0.23 0.085 0.41 0.101 0.015
J.E. Norman, et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 154 (2020) 102062
3
signiﬁcantly lower in the WM group compared to the LFLSM group. A
box and whisker plot of the oxylipins that are signiﬁcantly changed by
fasting or meal composition can be found in Fig. 1. sPLSDA plots for the
comparison of the cerebral oxylipin levels in the meal consuming
groups with and without the fasting group can be seen in Supplemental
Figure 1. No distinct clustering was seen when the fasting group was
included in the analysis; however, when the two meal consuming
groups were compared distinct clusters were formed.
3.3. Cerebral fatty acid composition
Brain fatty acid composition of the right hemisphere of cerebrum
was determined by gas-chromatography. The results of this analysis can
be seen in Table 3. None of the fatty acids were signiﬁcantly diﬀerent
between the fasted group and either meal consuming group as de-
termined by one-way ANOVA or the two meal-consuming groups when
analyzed by t-test. sPLSDA plots for the comparison of the cerebral fatty
acid composition of the meal consuming groups with and without the
fasting group can be seen in Supplemental Figure 2. As shown, no
distinct clustering was observed between the groups, consistent with
the lack of statistical signiﬁcance by one-way ANOVA or t-test.
3.4. Gene expression of oxylipin generating enzymes
RNA was isolated from the left hemisphere of cerebrum and gene
expression of oxylipin producing enzymes were determined by qRT-
PCR. The results of the gene expression analysis can be seen in Fig. 2.
The LFLSM and WM groups were found to have signiﬁcantly lower
expression of the cytochrome P450, family 2, subfamily j, polypeptide
12 (CYP2J12) than the fasted group. The expression of cyclooxygenases
(COX) 1 and 2, and epoxide hydrolase (EPHX)1 were signiﬁcantly
higher in the WM group when compared to the LFLSM group.
4. Discussion and conclusions
The main ﬁnding of this study is that cerebral oxylipin content is
aﬀected by acute fasting and a single high-fat/high-sucrose meal. We
did not observe any diﬀerences in cerebral fatty acid composition be-
tween fasted mice or mice that had consumed either meal type.
Although from our data it appears that brain fatty acid composition is
not aﬀected by the consumption of a single meal, perhaps there are
small changes that this study is not powered to detect. The changes in
some oxylipins appear to be linked to transcriptional changes in genes
involved in oxylipin synthesis and degradation. A summary of the ob-
served changes induced by fasting and meal composition can be found
in Fig. 3.
The mice in the two meal groups consumed the same amount of
food as measured by weight. However, due to the caloric density of the
food, the mice in the WM group consumed signiﬁcantly more calories
during the meal period. This does add a potential variable that could be
inﬂuencing the oxylipin changes we observed. Studies have demon-
strated that dietary restriction is protective in animal models of
Table 2
Brain oxylipin concentration expressed as pmol/g tissue.
Oxylipin Fasting Low-fat/low-sucrose meal (LFLSM) Western Meal (WM) p value
Mean (pmol/g) Standard Deviation Mean (pmol/g) Standard Deviation Mean (pmol/g) Standard Deviation ANOVA t-test LFLSM v WM
Linoleic Acid Derived
9-HODE 0.29 0.04 0.28 0.06 0.33 0.16 0.721 0.540
13-HODE 0.29 0.13 0.28 0.06 0.28 0.10 0.974 0.942
9,10,13-TriHOME 1.90 0.76 1.50 0.37 1.68 0.24 0.484 0.375
9,12,13-TriHOME 0.31 0.14 0.28 0.12 0.28 0.16 0.924 0.983
9-oxo-ODE 1.30 1.44 0.90 0.62 0.68 0.93 0.640 0.690
12(13)-EpOME 2.13 2.22 1.08 1.55 1.68 1.96 0.696 0.611
9,10-DiHOME 0.25 0.07 0.28 0.14 0.37 0.23 0.488 0.454
12,13-DiHOME 0.51 0.15 0.43 0.17 0.54 0.42 0.818 0.608
Dihomo-γ-linolenic acid derived
15(S)-HETrE 1.04 0.37 1.12 0.54 1.34 0.49 0.587 0.517
PGD1 2.71 0.98 2.97 0.72 4.47 1.05 0.022a 0.029
PGE1 0.82 0.41 0.85 0.33 1.07 0.52 0.621 0.460
Arachidonic acid derived
5-HETE 5.35 2.13 4.29 1.59 6.19 2.32 0.367 0.170
8-HETE 3.36 1.53 3.27 1.04 4.72 1.56 0.224 0.121
12-HETE 11.13 7.30 9.44 3.79 10.92 3.40 0.853 0.535
15-HETE 22.39 10.51 25.17 11.29 34.61 10.20 0.207 0.203
15-oxo-ETE 2.36 0.73 2.29 1.30 2.45 0.92 0.968 0.823
PGB2 1.13 0.52 0.88 0.12 0.86 0.12 0.360 0.783
PGD2 126.52 51.77 168.76 58.59 225.06 72.29 0.075 0.213
PGE2 21.11 11.29 27.49 11.72 37.90 11.07 0.102 0.187
PGF2a 37.83 15.98 43.38 16.94 48.32 14.67 0.593 0.635
6-keto-PGF1a 8.80 5.36 8.84 3.22 11.21 3.39 0.583 0.290
PGJ2 0.81 0.46 0.95 0.36 0.93 0.28 0.827 0.916
TXB2 18.17 8.65 18.18 6.52 20.63 5.50 0.818 0.539
5(6)-EpETrE 14.64 7.19 12.25 5.02 13.11 3.28 0.782 0.755
8(9)-EpETrE 9.53 8.04 5.02 1.41 7.34 0.60 0.352 0.010
11(12)-EpETrE 19.08 16.15 12.21 5.81 11.79 3.67 0.466 0.895
14(15)-EpETrE 59.70 70.08 29.52 15.19 22.38 12.08 0.360 0.434
11,12-DiHETrE 0.29 0.06 0.33 0.09 0.40 0.09 0.127 0.246
14,15-DiHETrE 0.35 0.07 0.32 0.06 0.46 0.08 0.015a 0.012
9-HETE 5.31 2.92 3.90 2.56 4.52 2.24 0.696 0.693
11-HETE 22.88 10.31 27.35 11.54 36.98 9.60 0.138 0.189
Docosahexaenoic acid derived
10(11)-EpDPE 1.96 0.45 1.64 0.43 1.92 0.45 0.467 0.336
16(17)-EpDPE 2.00 1.57 1.17 0.67 0.33 0.47 0.075 0.048
19(20)-EpDPE 3.31 2.86 2.88 0.82 3.40 1.42 0.897 0.498
Eicosapentaenoic acid derived
15-HEPE 5.14 2.06 2.89 0.86 3.80 1.61 0.121 0.295
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neurodegeneration and can reduce neuroinﬂammation [2,24]. There-
fore, in future studies it will be important to separate out the inﬂuence
of caloric intake from meal composition.
We saw a higher level of PGD1 in the brains of mice that consumed
a WM compared to those that consumed the LFLSM, as well as when
compared to mice in the fasted state. PGD1, a series 1 prostaglandin, is
formed by the action of COX 1 and 2 on dihomo-γ-linolenic acid (DGLA)
[25]. Our data indicated that both COX1 and COX2 gene expression
were higher in mice which consumed the WM when compared to the
LFLSM group, however no statistically signiﬁcant diﬀerences were
found when the fasting group was added to the analysis. Interestingly,
none of the other products of COX metabolism were found to be ele-
vated in the WM group. PGD1 has been shown to reduce vascular
permeability induced by other prostaglandins [26] and have anti-in-
ﬂammatory eﬀects in atopic dermatitis [27]. Further, PGD1 has been
shown to be generated by murine macrophages when incubated with
Fig. 1. Oxylipins modiﬁed by fasting or meal composition. Lipids were extracted from the right hemisphere of the cerebrum of fasting mice and mice after
consuming a low-fat/low-sucrose meal (LFLSM) or Western meal (WM). Oxylipins were measured by UHPLC-MS/MS. Data shown in box and whisker plot is as
follows: central line indicates median value, bottom of box indicates 25th percentile, top of box indicates 75th percentile, whiskers indicate lowest and highest
values, and X indicates the mean. # p< 0.05 when compared to LFLSM group by t-test, *p< 0.05 when compared to Fasting group by ANOVA with Holm-Sidak post
hoc (versus control) test.
Table 3
Brain fatty acid percent composition (% of total detected fatty acids).
Fatty Acid Fasting Low-fat/low-sucrose meal (LFLSM) Western meal (WM) p value
Mean (%) Standard Deviation Mean (%) Standard Deviation Mean (%) Standard Deviation ANOVA t-test LFLSM v WM
C13:0 3.9315 1.1938 3.9344 2.2779 3.5226 1.9170 0.922 0.765
C14:0 0.1720 0.0287 0.1637 0.0203 0.2632 0.1818 0.300 0.259
C14:1 0.2116 0.0673 0.2392 0.0573 0.2343 0.0366 0.708 0.876
C16:0 20.3504 6.8490 22.1384 0.3312 22.3584 1.0566 0.693 0.669
C16:1 0.7397 0.1507 0.6061 0.0983 0.8584 0.3123 0.201 0.123
C18:0 24.1695 4.6023 22.7945 1.9044 23.2786 2.3445 0.790 0.729
C18:1 cis 17.2129 3.0712 17.4695 1.3809 16.3767 0.2612 0.661 0.120
C18:1 trans 3.3693 0.3613 3.3862 0.2634 3.3037 0.2934 0.906 0.652
C18:2 n-6 0.5615 0.2565 0.6763 0.0923 0.6123 0.0366 0.537 0.187
C20:0 0.3311 0.0787 0.2766 0.1917 0.3235 0.0633 0.795 0.649
C20:1 n-9 1.9714 0.6006 2.1443 0.7324 1.8681 0.2672 0.745 0.451
C20:2 n-6 0.1186 0.0686 0.1203 0.0766 0.1512 0.0226 0.666 0.446
C20:3 0.6894 0.0963 0.6895 0.0831 0.6628 0.0403 0.821 0.536
C20:4 n-6 9.9940 1.9835 9.5567 0.8423 9.4554 1.0161 0.808 0.868
C20:5 n-3 0.0700 0.0456 0.0400 0.0365 0.0715 0.1258 0.685 0.477
C22:0 0.1289 0.1257 0.1361 0.1387 0.1126 0.1078 0.941 0.740
C22:2 0.5648 0.2260 0.6939 0.1763 0.7164 0.1779 0.439 0.846
C22:5n-6 0.1723 0.0282 0.0970 0.0915 0.1840 0.0347 0.0795 0.0786
C22:5 n-3 0.2857 0.0472 0.3127 0.0793 0.2453 0.0620 0.285 0.173
C22:6 14.9554 2.1701 14.5247 3.7033 15.4011 1.6795 0.875 0.643
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DGLA and stimulated with lipopolysaccharide [25]. We were unable to
ﬁnd much information on PGD1 in the literature, particularly its role in
the brain. However, at least in relation to atopic dermatitis, it appears
that it may be an anti-inﬂammatory mediator which is induced by in-
ﬂammatory stimuli as a potential feedback mechanism [25,26,27].
The cytochrome p450 epoxygenases can epoxidize any of the four
double bonds of arachidonic acid (AA) producing one of the following:
5,6-EpETrE, 8,9-EpETrE, 11,12-EpETrE, or 14,15-EpETrE [28]. The
action of epoxide hydrolases can then convert these products to 5,6-
DiHETrE, 8,9-DiHETrE, 11,12-DiHETrE, and 14,15-DiHETrE, respec-
tively [29]. The EpETrEs are generally considered to be beneﬁcial,
having have vasodilatory and anti-inﬂammatory eﬀects which are lost
upon conversion to DiHETrEs [30]. Others have demonstrated an in-
crease in DiHETrEs and other diol products of epoxide hydrolases in the
serum and brains of individuals with vascular cognitive impairment
compared with controls [31,32]. Our data indicated that epoxide 8,9-
EpETrE and diol 14,15-DiHETrE levels were higher in the WM group
compared to the LFLSM group and fasting group. This suggests possible
elevations in cytochrome P450 and soluble epoxide hydrolase meta-
bolic pathways in mice on the WM diet, which is why we decided to
look at their gene expression of the enzymes.
There are many cytochrome p450 enzymes, only some of which
have described functions and expression patterns reported in the
literature. The CYP2J family of enzymes have been reported to have AA
epoxygenase activity, forming EpETrEs from AA [20]. CYP2J9 and
CYP2J12 have been found to be expressed in brain tissue [20,33,34].
We examined the expression of these two enzymes. We saw no sig-
niﬁcant diﬀerence in the expression of these two enzymes between the
two meal consuming groups. However, CYP2J12 expression is lower in
both meal consuming groups when compared to the fasted group. It
seems that the expression of these cytochrome p450 enzymes do not
account for the diﬀerences in 8,9-EpETrE and 14,15-DiHETrE between
the LFLSM and WM groups.
Soluble epoxide hydrolase (sEH, encoded by the gene EPHX2) is
generally considered the relevant epoxide hydrolase for EpETrE con-
version to DiHETrEs, while microsomal epoxide hydrolase (mEH, en-
coded by the gene EPHX1) is considered to be the hydrolase responsible
for detoxifying xenobiotics [35]. sEH has been studied in the context of
neurodegenerative diseases and recovery after cerebral ischemia, with
deletion or inhibition of the enzyme providing neuroprotective and
anti-inﬂammatory eﬀects [3,31,36,37,38,39,40,41,42,43]. Marowsky
and colleagues demonstrated that both sEH and mEH are expressed in
brain, although with diﬀerent distributions, and are capable of cata-
lyzing the conversion of EpETrEs to DiHETrEs [29]. Further, mEH has
been shown to be upregulated in the hippocampus and cortex of Alz-
heimer's disease patients [44], indicating that there may also be a role
Fig. 2. Gene expression of oxylipin produ-
cing enzymes. RNA was isolated from the left
hemisphere of the cerebrum of fasting mice
and mice after consuming a low-fat/low-su-
crose meal (LFLSM) or Western meal (WM).
Gene expression was then measured by qRT-
PCR. Data shown in box and whisker plot is as
follows: central line indicates median value,
bottom of box indicates 25th percentile, top of
box indicates 75th percentile, whiskers in-
dicate lowest and highest values, and X in-
dicates the mean. #p < 0.05 when compared
to LFLSM group by t-test, *p < 0.05 when
compared to Fasting group by ANOVA with
Holm-Sidak post hoc (versus control) test.
Fig. 3. Summary of observed changes in-
duced by fasting and composition of a
single meal. Black arrows connect parent fatty
acids to oxylipins (solid outline), with the
genes of enzymes (solid black box) capable of
facilitating the production of these oxylipins
shown over the arrows. Green arrows pointing
up indicate a higher amount of the adjacent
gene/oxylipin in the indicated group when
compared to the low-fat/low-sucrose meal
(LFLSM) group. Red arrows pointing down in-
dicate a lower amount of the adjacent gene/
oxylipin in the indicated group when com-
pared to the LFLSM group. WM, Western meal.
(For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the
web version of this article.)
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for mEH in neurodegeneration and cognitive decline. We did not see
any diﬀerence in the expression of either epoxide hydrolase between
the fasted and either meal consuming groups; however, we did see an
increase in expression of EPHX1 in the WM mice when compared to the
LFLSM group. While we cannot conclude that mEH is responsible for
the elevated 14,15-DiHETrE levels, this study provides the basis for
further investigation into the role it plays in diet induced oxylipin
changes in brain.
The docosahexaenoic acid (DHA) derived oxylipin 16,17 EpDPE was
lower in the WM group than in the LFLSM group. This oxylipin appears
to have a vasodilatory eﬀect through activation of BK channels [45,46].
Reduced cerebral blood ﬂow has been found to be associated with
cognitive impairment in Alzheimer's disease [47]. Therefore, a reduc-
tion of this metabolite could be detrimental to cognitive function. It is
possible that the reduction in this metabolite was due to increased
metabolism by one of the epoxide hydrolases into DHA-diols, which
were not measured in this study.
We realize that there are a few limitations to this study. One lim-
itation is that the brains were not subjected to high-energy microwave
ﬁxation, a process known to prevent the eﬀects of postmortem ischemia
on brain oxylipins [48]. While use of the high-energy microwave would
have been ideal, we did not have access to one at the time of tissue
collection. Although this means that some of the oxylipin concentra-
tions in our samples were likely altered from the levels that existed in
the brains of the mice prior to post-mortem ischemia, we took care to
ensure that the tissue collection was conducted in a standardized
manner for all mice. We therefore believe that the diﬀerences in the
oxylipin levels between the two groups are a result of the meals con-
sumed. Another limitation of this study is that the mice were kept on
the vivarium provided bedding material, which is corn based. It is
possible that the mice consumed some of this, perhaps contributing to
some of the variability seen in the data. Future studies should control
for this by removing any edible bedding materials. Further, during the
meal training, mice were provided with the LFLSD, thus on the day of
the test meal mice in the WM group received a novel diet. It is possible
that the changes in oxylipin levels we observed were due to dietary
change rather than the WD itself. In future studies, it would be im-
portant to test this by meal training mice on both diets and using a
crossover design to assess meal composition and novelty simulta-
neously. This would allow analysis of which of these factors is leading
to changes in oxylipin levels.
In conclusion, while it has previously been shown that the oxylipin
content of the brain can be modiﬁed by changes in the composition of a
chronically consumed diet [12–17], in this study we demonstrate that a
single meal exposure is suﬃcient to produce diﬀerences in oxylipin
content. We also demonstrate that fasting alters brain oxylipin content.
We did not see any evidence of a signiﬁcant shift in fatty acid compo-
sition of the brain, which led us to look further at the gene expression of
the enzymes which generate oxylipins from their precursor fatty acids.
It appears that there is a change in the expression of some of these
enzymes. It is possible that there are diﬀerences in the activity and
substrate preference of these enzymes, which was not addressed by this
study. Caveats to be noted and taken into consideration are that al-
though there was no signiﬁcant diﬀerence in the amount of food con-
sumed, the higher caloric density of the WD led to a higher caloric
intake during the meal period in the WM group mice and these mice
received a novel diet for the test meal. While we can conclude that a
single meal has the potential to impact brain oxylipin levels, it remains
to be elucidated if this is a function of meal composition, quantity of
caloric intake, exposure to a novel diet, or some interaction of these
factors.
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Supplemental Data 
 
Supplemental Table 1. Calculated fatty acid content of LFLSD (Envigo TD.08485)  
Fatty acid g/kg diet 
Saturated fat 25.4 
Monounsaturated fat 13.7 
Polyunsaturated fat 9.3 
4:0 0.7 
6:0 0.6 
8:0 0.4 
10:0 0.9 
12:0 1.1 
14:0 4.1 
16:0 12.2 
16:1 0.6 
18:0 5.3 
18:1 (oleic) 13.0 
18:2 (linoleic) 8.3 
18:3 (linolenic) 1.2 
 
 
 
  
Supplemental Table 2. Typical fatty acid profile of WD (Envigo TD.88137) 
Fatty acid % of total fatty acids 
Saturated fat 61.8 
Monounsaturated fat 27.3 
Polyunsaturated fat 4.7 
4:0 2.1 
6:0 1.5 
8:0 1.1 
10:0 2.6 
12:0 3.3 
14:0 10.6 
16:0 28.9 
16:1 1.5 
18:0 12.5 
18:1 (oleic) 20.9 
18:1 isomers 4.0 
18:2 (linoleic) 2.3 
18:2 isomers 1.3 
18:3 (linolenic) 0.7 
  
Supplemental Table 3. Measured oxylipins and abbreviations.  
Oxylipins listed in grey were excluded from analyses due to detection in less than 3 samples 
per group. 
Oxylipin Abbreviation 
10(11)-epoxydocosapentaenoic acid 10(11)-EpDPE  
11(12)-epoxyeicosateteaenoic acid 11(12)-EpETE 
11(12)-epoxyeicosatrienoic acid 11(12)-EpETrE 
12(13)-epoxyoctadecamonoenoic acid 12(13)-EpOME 
13(14)-epoxydocosapentaenoic acid 13(14)-EpDPE 
14(15)-epoxyeicosateteaenoic acid  14(15)-EpETE 
14(15)-epoxyeicosatrienoic acid 14(15)-EpETrE 
16(17)-epoxydocosapentaenoic acid 16(17)-EpDPE 
17(18)-epoxyeicosateteaenoic acid 17(18)-EpETE 
19(20)-epoxydocosapentaenoic acid 19(20)-EpDPE 
5(6)-epoxyeicosatrienoic acid 5(6)-EpETrE 
7(8)-epoxydocosapentaenoic acid 7(8)-EpDPE 
8(9)-epoxyeicosateteaenoic acid 8(9)-EpETE 
8(9)-epoxyeicosatrienoic acid 8(9)-EpETrE 
9(10)-epoxyoctadecamonoenoic acid 9(10)-EpOME 
11,12-dihydroxyeicosatrienoic acid 11,12-DiHETrE 
12,13-dihydroxyoctadecamonoenoic acid 12,13-DiHOME 
14,15-dihydroxyeicosatetraenoic acid 14,15-DiHETE 
14,15-dihydroxyeicosatrienoic acid 14,15-DiHETrE 
17,18-dihydroxyeicosatetraenoic acid 17,18-DiHETE 
5,15-dihydroxyeicosatetraenoic acid 5,15-DiHETE 
5,6-dihydroxyeicosatetraenoic acid 5,6-DiHETE 
5,6-dihydroxyeicosatrienoic acid 5,6-DiHETrE 
8,15-dihydroxyeicosatetraenoic acid 8,15-DiHETE 
8,9-dihydroxyeicosatrienoic acid 8,9-DiHETrE 
9,10-dihydroxyoctadecamonoenoic acid 9,10-DiHOME 
6-keto-prostaglandin F1-α 6-keto-PGF1a 
13- hydroxyoctadecatrienoic acid acid 13-HOTrE 
13-hydroxyoctadecadienoic acid 13-HODE 
17- hydroxydocosahexaenoic acid 17-HDoHE 
9- hydroxyoctadecatrienoic acid acid 9-HOTrE 
9-hydroxyoctadecadienoic acid 9-HODE 
20-COOH- Leukotriene B4 20-COOH-LTB4 
20-OH-Leukotriene B4 20-OH-LTB4 
6-trans-leukotriene B4 6-trans-LTB4 
Leukotriene B3 LTB3 
Leukotriene B4 LTB4 
Leukotriene C4 LTC4 
Leukotriene D4 LTD4 
Leukotriene E4 LTE4 
Lipoxin A4 LXA4 
15-deoxy-Prostaglandin J2 15-deoxy-PGJ2 
9,10,13-trihydroxyoctadecamonoenoic acid 9,10,13-TriHOME 
9,12,13-trihydroxyoctadecamonoenoic acid 9,12,13-TriHOME 
Prostaglandin B2 PGB2 
Prostaglandin D1 PGD1 
Prostaglandin D2 PGD2 
Prostaglandin D3 PGD3 
Prostaglandin E1 PGE1 
Prostaglandin E2 PGE2 
Prostaglandin E3 PGE3 
Prostaglandin F2-α PGF2a 
Prostaglandin J2 PGJ2 
Resolvin E1 Resolvin E1 
Tromboxane B2 TXB2 
13-oxo-octadecadienoic acid 13-oxo-ODE 
20-hydroxyeicosatetraenoic acid 20-HETE 
9-oxo-octadecadienoic acid 9-oxo-ODE 
11-hydroxyeicosatetraenoic acid 11-HETE 
12-hydroxyeicosapentaenoic acid 12-HEPE 
12-hydroxyeicosatetraenoic acid 12-HETE 
12-oxo-eicosatetraenoic acid 12-oxo-ETE 
15-hydroxyeicosapentaenoic acid 15-HEPE 
15-hydroxyeicosatetraenoic acid 15-HETE 
15-oxo-eicosatetraenoic acid 15-oxo-ETE 
15(S)-hydroxyeicosatrienoic acid 15(S)-HETrE 
5-hydroxyeicosapentaenoic acid 5-HEPE 
5-hydroxyeicosatetraenoic acid 5-HETE 
5-oxo-eicosatetraenoic acid 5-oxo-ETE 
8-hydroxyeicosapentaenoic acid 8-HEPE 
8-hydroxyeicosatetraenoic acid 8-HETE 
9-hydroxyeicosatetraenoic acid 9-HETE 
    
  
Supplemental table 4. Gradient condition of LC-MS/MS analysis for oxylipin separation 
min B conc (%) flow (min/mL) 
0 35 0.3 
3 40 0.25 
4 48  
10 60  
20 70  
24 85  
24.5 85 0.25 
24.6 100 0.35 
26 100  
26.1 35 0.35 
27.3 35 0.3 
28 stop 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental Table 5. MRM pairs, optimized parameters and internal standards. 
Compound 
name 
Precursor 
Ion (m/z) 
Product Ion 
(m/z) 
Frag 
(V) 
CE (V) Cell 
Acc (V) 
Rt 
(min) 
Internal standard 
20-COOH-LTB4 365.2 347.2 120 7 4 4.0  d4-LTB4 
Resolvin E1 349.3 195 115 10 4 4.6 d4-PGE2 
d4-6-keto-PGF1a 373.3 167.1 90 19 4 4.7 - 
6-keto-PGF1a 369.3 163.2 90 22 4 4.7 d4-6-keto-PGF1a 
20-OH-LTB4 351.2 195.2 95 13 4 5.0  d4-LTB4 
d4-TXB2 373.3 173.2 105 10 4 6.1  - 
TXB2 369.2 169.1 80 10 4 6.1  d4-TXB2 
PGE3 349.3 269.2 120 7 4 6.2  d4-PGE2 
PGD3 349.3 269.2 120 7 4 6.5  d4-PGE2 
9,12,13-TriHOME 329.2 211.1 125 16 4 6.6 d4-PGE2 
9,10,13-TriHOME 329.2 171.1 110 16 4 6.7 d4-PGE2 
PGF2a 353.2 309.2 120 10 4 6.7 d4-PGE2 
d4-PGE2 355.2 275.3 90 7 4 7.0  - 
PGE2 351.2 271.3 80 10 4 7.0  d4-PGE2 
PGD1 353.3 317.2 75 7 4 7.2 d4-PGE2 
PGE1 353.3 317.2 75 7 4 7.3  d4-PGE2 
PGD2 351.2 271.3 80 10 4 7.3  d4-PGE2 
LTD4 495.3 177.1 55 13 4 7.8 d4-LTB4 
LXA4 351.2 115.2 95 10 4 8.1 d4-LTB4 
LTC4 624.3 272.1 70 22 4 9.6 d4-LTB4 
LTE4 438.2 333.3 90 13 4 9.7 d4-LTB4 
PGJ2 333.3 189.2 90 10 4 9.9 d4-PGE2 
PGB2 333.3 175.1 125 13 4 10.0  d4-PGE2 
6-trans-LTB4 335.2 195.1 125 7 4 10.8 d4-LTB4 
5,15-DiHETE 335.2 173.2 95 7 4 10.8  d11-14,15-DiHETrE 
5,6-DiHETE 335.2 115.2 90 4 4 10.9  d11-14,15-DiHETrE 
8,15-DiHETE 335.2 235.2 90 7 4 11.1  d11-14,15-DiHETrE 
17,18-DiHETE 335.3 247.2 105 7 4 11.7 d11-14,15-DiHETrE 
d4-LTB4 339.2 197.2 80 10 4 11.9 - 
LTB4 335.2 195.1 125 7 4 11.9 d4-LTB4 
14,15-DiHETE 335.3 207.2 95 7 4 12.3 d11-14,15-DiHETrE 
9,10-DiHOME 313.2 201.2 130 16 4 12.42 d11-14,15-DiHETrE 
12,13-DiHOME 313.2 183.2 130 16 4 12.7 d11-14,15-DiHETrE 
14,15-DiHETrE 337.2 207.1 130 10 4 13.8  d11-14,15-DiHETrE 
d11-14,15-
DiHETrE 
348.2 207.1 125 10 6 13.8 - 
LTB3 337.2 195.2 120 7 4 14.2 d4-LTB4 
11,12-DiHETrE 337.2 167.1 120 13 4 14.8 d11-14,15-DiHETrE 
9-HOTrE 293.2 171.2 110 4 4 15.3 d4-9HODE 
8,9-DiHETrE 337.2 127.1 85 13 4 15.6 d11-14,15-DiHETrE 
13-HOTrE 293.2 195.1 125 10 4 15.6 d4-9HODE 
15-deoxy-PGJ2 315.2 271.2 130 4 4 16.1 d4-PGE2 
d6-20-HETE 325.2 281.2 110 7 4 16.5 - 
20-HETE 319.2 275.1 125 10 4 16.5 d6-20-HETE 
15-HEPE 317.2 219.2 90 4 4 16.6 d8-5-HETE 
5,6-DiHETrE 337.2 145.1 85 7 4 16.7 d11-14,15-DiHETrE 
8-HEPE 317.2 155.2 115 7 4 17.0  d8-5-HETE 
12-HEPE 317.2 179.2 110 4 4 17.2 d8-5-HETE 
5-HEPE 317.2 115.1 115 4 4 17.8 d8-5-HETE 
d4-9HODE 299.2 172.3 90 13 4 18.0  - 
13-HODE 295.2 195.2 95 13 4 18.0  d4-9HODE 
9-HODE 295.2 171.1 120 10 4 18.0  d4-9HODE 
15-HETE 319.2 219.2 120 4 4 19.1 d8-5-HETE 
17(18)-EpETE 317.2 215.2 130 4 4 19.2 d-11-11(12)EpEtrE 
13-oxo-ODE 293.2 195.1 95 13 4 19.3 d6-20-HETE 
17-HDoHE 343.2 281.2 95 4 4 19.5 d4-9HODE 
11-HETE 319.2 167.2 100 7 4 19.5 d8-5-HETE 
9-HETE 319.2 167.2 80 7 4 19.8 d8-5-HETE 
9-oxo-ODE 293.2 185.1 90 13 4 20.0  d6-20-HETE 
15-oxo-ETE 317.2 113.1 125 10 6 20.1 d8-5-HETE 
14(15)-EpETE 317.2 207.2 100 4 4 20.2 d-11-11(12)EpEtrE 
  
 
 
 
8-HETE 319.2 155.2 120 7 4 20.4 d8-5-HETE 
11(12)-EpETE 317.2 167.2 90 4 4 20.5 d-11-11(12)EpEtrE  
12-HETE 319.2 179.2 120 7 4 20.5 d8-5-HETE 
8(9)-EpETE 317.2 127.2 115 4 4 20.8 d-11-11(12)EpEtrE 
12-oxo-ETE 317.2 153.1 115 7 4 21.1 d8-5-HETE 
15(S)-HETrE 321.2 221.2 85 7 4 21.1 d8-5-HETE 
5-HETE 319.2 115.1 90 10 4 21.2  d8-5-HETE 
d8-5-HETE 327.2 116.1 75 7 4 21.2 - 
12(13)EpOME 295.3 195.2 95 7 4 22.5 d-11-11(12)EpEtrE 
19(20)-EpDPE 343.2 241.2 130 7 4 22.5 d-11-11(12)EpEtrE 
14(15)-EpETrE 319.2 219.3 130 4 4 22.8 d-11-11(12)EpEtrE 
9(10)-EpOME 295.3 171.1 100 7 4 22.8 d-11-11(12)EpEtrE 
16(17)-EpDPE 343.2 233.2 130 4 4 23.3 d-11-11(12)EpEtrE 
13(14)-EpDPE 343.2 193.2 80 4 4 23.4 d-11-11(12)EpEtrE 
5-oxo-ETE 317.2 273.2 120 7 4 23.4 d8-5-HETE 
11(12)-EpETrE 319.2 167.2 105 4 4 23.5  d-11-11(12)EpEtrE 
d-11-
11(12)EpEtrE 
330.2 167.2 80 7 4 23.5 - 
10(11)-EpDPE 343.2 153.2 90 4 4 23.6 d-11-11(12)EpEtrE  
7(8)-EpDPE 343.2 113.1 85 4 4 23.8 d-11-11(12)EpEtrE 
8(9)-EpETrE 319.2 167.2 90 4 4 23.9  d-11-11(12)EpEtrE 
5(6)-EpETrE 319.2 191.1 115 4 4 24.2 d-11-11(12)EpEtrE 
Supplemental Table 6.   Recovery of surrogates by group. 
Surrogate 
Fasting Low-fat/low-sucrose meal (LFLSM) Western Meal (WM) p value 
Mean 
(%) 
Standard 
Deviation 
Mean 
(%) 
Standard 
Deviation 
Mean 
(%) 
Standard 
Deviation ANOVA 
t-test 
LFLSM 
v WM 
d11-11(12)- 
EpEtrE 34.643 19.264 29.940 9.119 33.956 19.408 0.891 0.686 
d11-14,15-
DiHETrE 59.941 15.646 58.773 13.197 59.124 14.311 0.991 0.969 
d4-6keto- 
PGF1α 56.338 11.087 59.775 6.913 60.113 12.572 0.822 0.959 
d4-9- 
HODE 51.735 18.148 49.774 16.198 52.259 20.367 0.975 0.836 
d4-LTB4 40.559 11.143 40.326 14.728 42.168 11.507 0.969 0.831 
d4-PGE2 64.338 12.363 65.267 7.004 65.322 10.095 0.985 0.992 
d4-TXB2 57.683 8.988 57.720 6.528 61.773 8.261 0.659 0.414 
d6-20-HETE 64.828 14.835 61.253 15.328 61.216 14.326 0.908 0.997 
d8-5-HETE 32.091 18.161 26.703 11.899 27.586 18.461 0.859 0.931 
  
Supplemental Table 7. Primer sequences used for qRT-PCR 
Gene Forward Primer Reverse Primer 
18s GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA 
COX1 AGCCTGAGCGGGAATAGTG ATGGGCAGTTACGATAACATTGT 
COX2 AATTGCTCTCCCCTCTCTACG GGTTTTAGGTCGTTTGTTGGGAT 
EPHX1 GGAGACCTTACCACTTGAAGATG GCCCGGAACCTATCTATCCTCT 
EPHX2 CTTGGTGCGTACCAGACGG TTCTAGGTAGATTGGCTCCA 
CYP2J9 GGGAATGTTCTAAGCCTGGATTT GAGTGACTGGGCGATTCATAAA 
CYP2J12 AAGGAGGCTGACTGTCTTGTGG GACTGTCCTCATACTCAAAGCGC 
 
  
 Supplemental Figure 1. sPLSDA plots of free oxylipin content of cerebrum.  
The lipids from the right hemisphere of cerebrum were extracted from fasting mice and mice 
after consuming a low-fat/low-sucrose meal (LFLSM) or Western meal (WM).  The free oxylipin 
content was determined by UHPLC/MS/MS.  sPLSDA plots are shown of all three groups A or 
the two meal consuming groups B. 
  
 
Supplemental Figure 2. sPLSDA plots of fatty acid composition of cerebrum.  
The lipids from the right hemisphere of cerebrum were extracted from fasting mice and mice 
after consuming a low-fat/low-sucrose meal (LFLSM) or Western meal (WM).  Fatty acid 
composition was determined by gas chromatography.  sPLSDA plots are shown of all three 
groups A or the two meal consuming groups B. 
 
 
 
